Abstract
After a 75-year-old man was diagnosed with lung cancer, proximal weakness and myalgia in the bilateral lower extremities developed, and the creatinine kinase (CK) level was elevated. The anti-Mi-2 antibody test was positive, muscle T2-weighted/fat-suppressed magnetic resonance imaging showed high intensity, and there were no skin lesions. Therefore, he was diagnosed with lung cancer-associated polymyositis (PM). The lung tumour shrank after chemotherapy, accompanied by gradual improvement of his PM-derived symptoms and CK level. Although positive anti-Mi-2 antibody tests rarely indicate PM and cancer, examining myositis-specific autoantibodies, including anti-Mi-2, should be considered if the CK level increases after a cancer diagnosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data used during the current report are available from the corresponding author on reasonable request.
Abbreviations
- PM:
-
Polymyositis
- DM:
-
Dermatomyositis
- IP:
-
Interstitial pneumonitis
- CT:
-
Computed tomography
- CPFE:
-
Combined pulmonary fibrosis and emphysema
- CK:
-
Creatinine kinase
- ANA:
-
Antinuclear antibody
- TIF1-γ:
-
Anti-transcriptional intermediary factor 1-γ
- IVIg:
-
Intravenous immunoglobulin
- MRI:
-
Magnetic resonance imaging
- UIP:
-
Usual interstitial pneumonia
- ELISA:
-
Enzyme-linked immunosorbent assay
References
Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A (2005) Anti-Mi-2 antibodies. Autoimmunity 38(1):79–83
Richards M, Garcia-De La Torre I, Gonzalez-Bello YC, Vazquez-Del Mercado M, Andrade-Ortega L, Medrano-Ramirez G, Navarro-Zarza JE, Maradiaga-Cecena M, Loyo E, Rojo-Mejia A, Gomez G, Seaman A, Fritzler MJ, Koenig M, Mahler M (2019) Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 58(9):1655–1661
McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14(5):290–302
Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV (2010) Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 6(2):108–119
Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, Lu X, Shu X, Zhang S, Wang G (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259
Zhao Y, Su H, Yin X, Hou H, Wang Y, Xu Y, Li X, Zhang N, Sun W, Wei W (2023) Cancer associated autoantibodies in idiopathic inflammatory myopathies: a retrospective cohort from a single center in China. Med Clin (Barc) 160:10–16
Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Danko K (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35(3):438–444
Tomii K, Kato T, Takahashi M, Noma S, Kobashi Y, Enatsu S, Okubo S, Kobayashi N, Kudoh S (2017) Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Jpn J Clin Oncol 47(4):350–356
Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28(6):913–921
Opinc AH, Makowska JS (2022) Update on malignancy in myositis-well-established association with unmet needs. Biomolecules 12(1):111
Khamooshi P, Pavonm M, Kang-Yoonsun C, Viviana Reyes P, Augustine Mathew M (2022) A rare case of paraneoplastic dermatomyositis in a patient with metastatic endometrial cancer. Ann Intern Med Clin Cases 1:e220480
Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, Martel C, Masseau A, Meyer A, Terrier B, Guegan S, Verneuil L, Audia S, Livideanu CB, Hachulla E, Kahn JE, Lefevre G, Maurier F, Moulis G, Papo T, Dossier A, Descamps V, Salort-Campana E, Richard MA, Bergot E, Mortier L, Costedoat-Chalumeau N, Genot S, Perez F, Piette AM, Samson M, Schleinitz N, Zenone T, Lacoste M, de Boysson H, Madaule S, Rigolet A, Champtiaux N, Hervier B, Bouvier AM, Jooste V, Leonard-Louis S, Maisonobe T, Aouba A, Benveniste O, Bienvenu B, Allenbach Y, French Myositis Network (2020) Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol 83(6):1759–1763
Nawata T, Kubo M, Oishi K, Murata Y, Oishi M, Okazaki Y, Omoto M, Okazaki Y, Kanda T, Kuwana M, Yano M (2019) A case of cancer-associated myositis with anti-Mi-2 antibody: false-positive anti-transcriptional intermediary factor 1-gamma antibody by commercial enzyme-linked immunosorbent assay. Int J Rheum Dis 22(7):1335–1339
Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, Mosca M, Vencovsky J, van Venrooij WJ, van Engelen BG (2006) Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 65(2):242–245
Moll SA, Platenburg M, Platteel ACM, Vorselaars ADM, Janssen Bonas M, Kraaijvanger R, Roodenburg-Benschop C, Meek B, van Moorsel CHM, Grutters JC (2022) Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases. PLoS One 17(11):e0277007
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors state that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Shimoda, M., Tanaka, Y., Taniguchi, A. et al. Anti-Mi-2 antibody-positive lung cancer-associated polymyositis. Int Canc Conf J 12, 173–176 (2023). https://doi.org/10.1007/s13691-023-00601-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-023-00601-1